A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

However, the PSA progression-free survival and radiographic progression-free survival was not statistically significant. Both of these endpoints were trending toward better outcomes with ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The European Commission on Friday approved AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKNY) Enhertu (trastuzumab ...

Vepdegestrant met the primary endpoint in ESR1-mutant breast cancer, significantly improving progression-free survival over fulvestrant. The trial did not achieve statistical significance for PFS ...

The study also showed that the combination therapy prolonged secondary endpoints, including intracranial progression-free survival and time to symptomatic progression. The safety profile of ...

The lackluster overall survival data came in stark contrast with the massive 78% and 60% progression-free survival improvements that Cabometyx has shown in the two patient subgroups, respectively.

Progression-free survival (PFS), time-to-progression (TTP) and overall survival (OS) are commonly used endpoints in randomised controlled trials (RCTs) and observational studies of treatments for ...